Expression of survivin does not appear to influence breast cancer recurrence risk

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies—improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26:1533–1546.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Anderson BO, Balassanian R, et al. Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14:324–354.
   PubMed Web of Science ®Google Scholar
• Voduc KD, Cheang MC, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684–1691.
   PubMed Web of Science ®Google Scholar
• Cross M, Dexter TM. Growth factors in development, transformation, and tumorigenesis. Cell. 1991;64:271–280.
   PubMed Web of Science ®Google Scholar
• Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev. 1999;13:239–252.
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–921.
   PubMed Web of Science ®Google Scholar
• Shin S, Sung B-J, Cho Y-S, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001;40:1117–1123.
   PubMed Web of Science ®Google Scholar
• Dubrez-Daloz L, Dupoux A, Cartier J. IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle. 2008;7:1036–1046.
   PubMed Web of Science ®Google Scholar
• Mita AC, Mita MM, Nawrocki ST, et al. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14:5000–5005.
   PubMed Web of Science ®Google Scholar
• Zhao J, Tenev T, Martins LM, et al. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci. 2000;113:4363–4371.
   PubMed Web of Science ®Google Scholar
• Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46–54.
   PubMed Web of Science ®Google Scholar
• Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. 2009;35:553–562.
   PubMed Web of Science ®Google Scholar
• Fortugno P, Wall NR, Giodini A, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci. 2002;115:575–585.
   PubMed Web of Science ®Google Scholar
• Athanassiadou AM, Patsouris E, Tsipis A, et al. The significance of survivin and nectin-4 expression in the prognosis of breast carcinoma. Folia Histochem Cytobiol. 2011;49:26–33. Epub 2011/04/29.
   PubMed Web of Science ®Google Scholar
• Kennedy S, O'Driscoll L, Purcell R, et al. Prognostic importance of survivin in breast cancer. Br J Cancer. 2003;88:1077–1083.
   PubMed Web of Science ®Google Scholar
• Song J, Su H, Zhou YY, et al. Prognostic value of survivin expression in breast cancer patients: a meta-analysis. Tumor Biol. 2013;34:2053–2062. Epub 2013/05/22.
   PubMedGoogle Scholar
• O'Driscoll L, Linehan R, SMK, Cronin D Purcell R, Glynn S, et al. Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer. Cancer Lett. 2003;201:225–236. Epub 2003/11/11.
   PubMed Web of Science ®Google Scholar
• Jensen M-B, Laenkholm A-V, Offersen BV, et al. The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016. Acta Oncol. 2018;57:13–18.
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Offersen BV, Overgaard J, et al. Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. Acta Oncol. 2018;57:3–12.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. Chichester, West Sussex, UK; Hoboken, NJ: John Wiley & Sons; 2011.
   Google Scholar
• Schmidt M, Pedersen L, Sørensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29:541–549.
   PubMed Web of Science ®Google Scholar
• Erichsen R, Lash TL, Hamilton-Dutoit SJ, et al. Existing data sources for clinical epidemiology: the Danish national pathology registry and data bank. Clinical Epidemiol. 2010;2:51–56. Epub 2010/09/25. PubMed PMID: 20865103; PubMed Central PMCID: PMCPMC2943174.
   PubMedGoogle Scholar
• Kononen J, Bubendorf L, Kallionimeni A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844–847.
   PubMed Web of Science ®Google Scholar
• Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–168. Epub 1998/03/21.
   PubMed Web of Science ®Google Scholar
• McCarty KS, Jr., Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109:716–721. Epub 1985/08/01.
   PubMed Web of Science ®Google Scholar
• Andersen KW, Mouridsen H. Danish breast cancer cooperative group (DBCG): a description of the register of the nation-wide programme for primary breast cancer. Acta Oncol. 1988;27:627–647.
   PubMed Web of Science ®Google Scholar
• Brennan DJ, Rexhepaj E, O'Brien SL, et al. Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res. 2008;14:2681–2689.
   PubMed Web of Science ®Google Scholar
• Li Y, Ma X, Wu X, et al. Prognostic significance of survivin in breast cancer: meta-analysis. Breast J. 2014;20:514–524. Epub 2014/07/22.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127–134.
   PubMed Web of Science ®Google Scholar
• Møller S, Jensen M-B, Ejlertsen B, et al. The clinical database and the treatment guidelines of the Danish breast cancer cooperative group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47:506–524.
   PubMed Web of Science ®Google Scholar
• Lash TL, Cronin-Fenton D, Ahern TP, et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst. 2011;103:489–500.
   PubMed Web of Science ®Google Scholar